Another effective therapy is targeted therapy (TAR), the current recommended agents in this category include selective BRAF inhibitor (BRAFi), MEK inhibitor (MEKi) and KIT inhibitor (KITi).9 Based on the fact that approximately 50% of melanoma harbor BRAF gene activating point mutations10, development and approval of BRAFi have been applied in melanoma patients. Here, MAP2K7 is linked to melanoma.